Skip to main content
Erschienen in: Journal of Gastroenterology 9/2012

01.09.2012 | Original Article—Liver, Pancreas, and Biliary Tract

Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT

verfasst von: Tatsuo Inoue, Masatoshi Kudo, Mina Komuta, Sosuke Hayaishi, Taisuke Ueda, Masahiro Takita, Satoshi Kitai, Kinuyo Hatanaka, Norihisa Yada, Satoru Hagiwara, Hobyung Chung, Toshiharu Sakurai, Kazuomi Ueshima, Michiie Sakamoto, Osamu Maenishi, Tomoko Hyodo, Masahiro Okada, Seishi Kumano, Takamichi Murakami

Erschienen in: Journal of Gastroenterology | Ausgabe 9/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to evaluate gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) for the detection of hepatocellular carcinomas (HCCs) and dysplastic nodules (DNs) compared with dynamic multi-detector row computed tomography (MDCT), and to discriminate between HCCs and DNs.

Methods

Eighty-six nodules diagnosed as HCC or DNs were retrospectively investigated. Gd-EOB-DTPA-enhanced MRI and dynamic MDCT were compared with respect to their diagnostic ability for hypervascular HCCs and detection sensitivity for hypovascular tumors. The ability of hepatobiliary images of Gd-EOB-DTPA-enhanced MRI to discriminate between these nodules was assessed. We also calculated the EOB enhancement ratio of the tumors.

Results

For hypervascular HCCs, the diagnostic ability of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of MDCT for tumors less than 2 cm (p = 0.048). There was no difference in the detection of hypervascular HCCs between hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI (43/45: 96%) and dynamic MDCT (40/45: 89%), whereas the detection sensitivity of hypovascular tumors by Gd-EOB-DTPA-enhanced MRI was significantly higher than that by dynamic MDCT (39/41: 95% vs. 25/41: 61%, p = 0.001). EOB enhancement ratios were decreased in parallel with the degree of differentiation in DNs and HCCs, although there was no difference between DNs and hypovascular well-differentiated HCCs.

Conclusion

The diagnostic ability of Gd-EOB-DTPA-enhanced MRI for hypervascular HCCs less than 2 cm was significantly higher than that of MDCT. For hypovascular tumors, the detection sensitivity of hepatobiliary phase images of Gd-EOB-DTPA-enhanced MRI was significantly higher than that of dynamic Gd-EOB-DTPA-enhanced MRI and dynamic MDCT. It was difficult to distinguish between DNs and hypovascular well-differentiated HCCs based on the EOB enhancement ratio.
Literatur
1.
Zurück zum Zitat Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology. 2004;47:191–8.PubMedCrossRef Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers. Intervirology. 2004;47:191–8.PubMedCrossRef
2.
Zurück zum Zitat Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis. 1999;19:297–309.PubMedCrossRef Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions. Semin Liver Dis. 1999;19:297–309.PubMedCrossRef
3.
Zurück zum Zitat Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991;178:493–7.PubMed Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology. 1991;178:493–7.PubMed
4.
Zurück zum Zitat Takayasu K, Muramatsu Y, Furukawa H, Wakao F, Moriyama N, Takayama T, et al. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. Radiology. 1995;194:101–5.PubMed Takayasu K, Muramatsu Y, Furukawa H, Wakao F, Moriyama N, Takayama T, et al. Early hepatocellular carcinoma: appearance at CT during arterial portography and CT arteriography with pathologic correlation. Radiology. 1995;194:101–5.PubMed
5.
Zurück zum Zitat Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, et al. Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res. 2003;27:196–204.PubMedCrossRef Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, et al. Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res. 2003;27:196–204.PubMedCrossRef
6.
Zurück zum Zitat Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology. 2000;32:205–12.PubMedCrossRef Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology. 2000;32:205–12.PubMedCrossRef
7.
Zurück zum Zitat Inoue T, Kudo M, Watai R, Pei Z, Kawasaki T, Minami Y, et al. Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol. 2005;40:1139–47.PubMedCrossRef Inoue T, Kudo M, Watai R, Pei Z, Kawasaki T, Minami Y, et al. Differential diagnosis of nodular lesions in cirrhotic liver by post-vascular phase contrast-enhanced US with Levovist: comparison with superparamagnetic iron oxide magnetic resonance images. J Gastroenterol. 2005;40:1139–47.PubMedCrossRef
8.
Zurück zum Zitat Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785–92.PubMed Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195:785–92.PubMed
9.
Zurück zum Zitat Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT—a multicenter trial. J Comput Assist Tomogr. 2006;30:345–54.PubMedCrossRef Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT—a multicenter trial. J Comput Assist Tomogr. 2006;30:345–54.PubMedCrossRef
10.
Zurück zum Zitat Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405–13.PubMedCrossRef Kogita S, Imai Y, Okada M, Kim T, Onishi H, Takamura M, et al. Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow. Eur Radiol. 2010;20:2405–13.PubMedCrossRef
11.
Zurück zum Zitat [No authors listed]. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology. 1995;22:983–993. [No authors listed]. Terminology of nodular hepatocellular lesions. International Working Party. Hepatology. 1995;22:983–993.
12.
Zurück zum Zitat The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology. 2009;49:658–64. The International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular Neoplasia. Hepatology. 2009;49:658–64.
13.
Zurück zum Zitat Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology. 2008;51(Suppl 1):42–5.PubMedCrossRef Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology. 2008;51(Suppl 1):42–5.PubMedCrossRef
14.
Zurück zum Zitat Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725–34.PubMedCrossRef Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology. 2007;45:725–34.PubMedCrossRef
15.
Zurück zum Zitat Kim YK, Kim CS, Han YM, Kwak HS, Jin GY, Hwang SB, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi- detector row computed tomography. J Comput Assist Tomogr. 2009;33:844–50.PubMedCrossRef Kim YK, Kim CS, Han YM, Kwak HS, Jin GY, Hwang SB, et al. Detection of hepatocellular carcinoma: gadoxetic acid-enhanced 3-dimensional magnetic resonance imaging versus multi- detector row computed tomography. J Comput Assist Tomogr. 2009;33:844–50.PubMedCrossRef
16.
Zurück zum Zitat Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009;192:1675–81.PubMedCrossRef Kim SH, Kim SH, Lee J, Kim MJ, Jeon YH, Park Y, et al. Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma. AJR Am J Roentgenol. 2009;192:1675–81.PubMedCrossRef
17.
Zurück zum Zitat Akai H, Kiryu S, Matsuda I, Satou J, Takao H, Tajima T, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol. 2011;80:310–5.PubMedCrossRef Akai H, Kiryu S, Matsuda I, Satou J, Takao H, Tajima T, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol. 2011;80:310–5.PubMedCrossRef
18.
Zurück zum Zitat Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR Imaging and 64-Section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256:806–16.PubMedCrossRef Di Martino M, Marin D, Guerrisi A, Baski M, Galati F, Rossi M, et al. Intraindividual comparison of gadoxetate disodium-enhanced MR Imaging and 64-Section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis. Radiology. 2010;256:806–16.PubMedCrossRef
19.
Zurück zum Zitat Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459–66.PubMedCrossRef Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459–66.PubMedCrossRef
20.
Zurück zum Zitat Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002;225:143–9.PubMedCrossRef Hayashi M, Matsui O, Ueda K, Kawamori Y, Gabata T, Kadoya M. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology. 2002;225:143–9.PubMedCrossRef
21.
Zurück zum Zitat Kudo M, Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72(suppl 1):2–15.PubMedCrossRef Kudo M, Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology. 2007;72(suppl 1):2–15.PubMedCrossRef
22.
Zurück zum Zitat Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol. 2002;178:885–97.PubMed Tajima T, Honda H, Taguchi K, Asayama Y, Kuroiwa T, Yoshimitsu K, et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. AJR Am J Roentgenol. 2002;178:885–97.PubMed
23.
Zurück zum Zitat Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. 27. J Gastroenterol. 2009;44(Suppl 19):112–8.PubMedCrossRef Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. 27. J Gastroenterol. 2009;44(Suppl 19):112–8.PubMedCrossRef
Metadaten
Titel
Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT
verfasst von
Tatsuo Inoue
Masatoshi Kudo
Mina Komuta
Sosuke Hayaishi
Taisuke Ueda
Masahiro Takita
Satoshi Kitai
Kinuyo Hatanaka
Norihisa Yada
Satoru Hagiwara
Hobyung Chung
Toshiharu Sakurai
Kazuomi Ueshima
Michiie Sakamoto
Osamu Maenishi
Tomoko Hyodo
Masahiro Okada
Seishi Kumano
Takamichi Murakami
Publikationsdatum
01.09.2012
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 9/2012
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-012-0571-6

Weitere Artikel der Ausgabe 9/2012

Journal of Gastroenterology 9/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.